Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CHARLES CLEELAND and QIULING SHI.
Connection Strength

8.138
  1. Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. JCO Oncol Pract. 2020 09; 16(9):e893-e901.
    View in: PubMed
    Score: 0.725
  2. Interpreting Patient-reported Outcome Scores for Clinical Research and Practice: Definition, Determination, and Application of Cutpoints. Med Care. 2019 05; 57 Suppl 5 Suppl 1:S8-S12.
    View in: PubMed
    Score: 0.676
  3. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017 06; 158(6):1108-1112.
    View in: PubMed
    Score: 0.592
  4. Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. Eur J Cancer. 2016 11; 67:83-90.
    View in: PubMed
    Score: 0.563
  5. Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer. J Pain Symptom Manage. 2016 12; 52(6):822-831.
    View in: PubMed
    Score: 0.560
  6. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46.
    View in: PubMed
    Score: 0.498
  7. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res. 2013 Nov; 22(9):2331-9.
    View in: PubMed
    Score: 0.442
  8. Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain. 2013 Mar; 14(3):290-6.
    View in: PubMed
    Score: 0.441
  9. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer. 2011 Jun 15; 117(12):2779-90.
    View in: PubMed
    Score: 0.387
  10. Does recall period have an effect on cancer patients' ratings of the severity of multiple symptoms? J Pain Symptom Manage. 2010 Aug; 40(2):191-9.
    View in: PubMed
    Score: 0.366
  11. Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. J Pain Symptom Manage. 2009 Feb; 37(2):168-74.
    View in: PubMed
    Score: 0.321
  12. People in pain: how do they seek relief? J Pain. 2007 Aug; 8(8):624-36.
    View in: PubMed
    Score: 0.297
  13. Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Support Care Cancer. 2021 Oct; 29(10):6099-6107.
    View in: PubMed
    Score: 0.193
  14. The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. J Patient Rep Outcomes. 2020 Feb 19; 4(1):15.
    View in: PubMed
    Score: 0.179
  15. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.
    View in: PubMed
    Score: 0.169
  16. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35.
    View in: PubMed
    Score: 0.135
  17. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain. 2015 Oct; 16(10):1032-43.
    View in: PubMed
    Score: 0.130
  18. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.
    View in: PubMed
    Score: 0.117
  19. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012 Jul; 26(5):699-705.
    View in: PubMed
    Score: 0.102
  20. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol. 2011 Mar 10; 29(8):994-1000.
    View in: PubMed
    Score: 0.095
  21. Biological pathways and genetic variables involved in pain. Qual Life Res. 2010 Dec; 19(10):1407-17.
    View in: PubMed
    Score: 0.093
  22. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010 Jan 01; 116(1):137-45.
    View in: PubMed
    Score: 0.089
  23. Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma. J Patient Rep Outcomes. 2024 Dec 04; 8(1):141.
    View in: PubMed
    Score: 0.062
  24. Patient-reported outcomes after oncologic hepatic resection predict the risk of delayed readiness to return to intended oncologic therapy (RIOT). Eur J Surg Oncol. 2024 Jul; 50(7):108396.
    View in: PubMed
    Score: 0.060
  25. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers (Basel). 2023 Jun 04; 15(11).
    View in: PubMed
    Score: 0.056
  26. Patient-reported symptoms at discharge and risk of complications after gynecologic surgery. Int J Gynecol Cancer. 2023 02 06; 33(2):271-277.
    View in: PubMed
    Score: 0.055
  27. Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep. Eur J Oncol Nurs. 2021 Jun; 52:101959.
    View in: PubMed
    Score: 0.049
  28. Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. Gynecol Oncol. 2021 04; 161(1):83-88.
    View in: PubMed
    Score: 0.048
  29. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 10; 16(10):e1151-e1160.
    View in: PubMed
    Score: 0.046
  30. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer. 2021 Jan; 29(1):467-475.
    View in: PubMed
    Score: 0.045
  31. A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. J Pain Symptom Manage. 2020 05; 59(5):1052-1058.e1.
    View in: PubMed
    Score: 0.044
  32. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):100-107.
    View in: PubMed
    Score: 0.044
  33. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019 10; 58(4):662-671.
    View in: PubMed
    Score: 0.043
  34. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol. 2019 03; 152(3):492-500.
    View in: PubMed
    Score: 0.042
  35. Assessment of baseline symptom burden in treatment-na?ve patients with lung cancer: an observational study. Support Care Cancer. 2019 Sep; 27(9):3439-3447.
    View in: PubMed
    Score: 0.041
  36. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
    View in: PubMed
    Score: 0.041
  37. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018 06; 27(6):1563-1570.
    View in: PubMed
    Score: 0.039
  38. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1107-14.
    View in: PubMed
    Score: 0.034
  39. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
    View in: PubMed
    Score: 0.034
  40. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.
    View in: PubMed
    Score: 0.033
  41. Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. J Thorac Cardiovasc Surg. 2015 Sep; 150(3):613-9.e2.
    View in: PubMed
    Score: 0.032
  42. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41.
    View in: PubMed
    Score: 0.031
  43. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct; 11(5):587-99.
    View in: PubMed
    Score: 0.025
  44. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74.
    View in: PubMed
    Score: 0.023
  45. The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet. 2009 Jun; 12(3):301-11.
    View in: PubMed
    Score: 0.021
  46. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008 Oct 15; 113(8):2102-9.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.